Merck & Co Inc (MRK)

MRK on New York Consolidated

59.58USD
19 Dec 2014
Price Change (% chg)

$0.60 (+1.02%)
Prev Close
$58.98
Open
$59.25
Day's High
$59.90
Day's Low
$59.01
Volume
17,374,218
Avg. Vol
11,302,256
52-wk High
$62.20
52-wk Low
$48.53

MRK

Chart for MRK

About

Merck & Co., Inc. is a health care company that offers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are comprised of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.34
Market Cap (Mil.): $169,855.00
Shares Outstanding (Mil.): 2,850.87
Dividend: 0.45
Yield (%): 3.02

Financials

  MRK Industry Sector
P/E (TTM): 32.66 37.83 38.47
EPS (TTM): 1.82 -- --
ROI: 6.72 18.99 18.25
ROE: 11.63 19.75 19.13
Search Stocks

UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data

* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s

18 Dec 2014

Tetraphase's antibiotic succeeds late-stage trial, shares rise

- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck & Co Inc's ertapenem in a late-stage study.

17 Dec 2014

UPDATE 2-Tetraphase's antibiotic succeeds late-stage trial, shares rise

* Shares rise 17.5 pct in extended trading (Adds details from conference call, analyst quotes)

17 Dec 2014

Tetraphase's antibiotic succeeds in late-stage trial

Dec 17 - Tetraphase Pharmaceuticals Inc said its antibiotic drug to treat complicated intra-abdominal infections was as effective as Merck & co Inc's ertapenem in a late-stage study.

17 Dec 2014

TRLPC: Merck looks for $8B bridge for Cubist acquisition

NEW YORK, Dec 15 - Merck & Co Inc is approaching banks about an $8 billion, 364-day bridge loan that will back the drugmaker's plans to acquire Cubist Pharmaceuticals Inc, sources told Thomson Reuters LPC.

15 Dec 2014

CORRECTED-India caps prices of 52 more "essential" drugs - pricing authority

(Corrects paragraph 4 to say Merck Ltd is a unit of Merck KGaA, not Merck & Co Inc)

12 Dec 2014

UPDATE 2-Ebola vaccine trial halted temporarily after joint pains -Geneva hospital

* Lausanne says safety data "satisfactory" in GSK vaccine trial (Adds statement on GSK Ebola vaccine, new paras 4-7)

11 Dec 2014

UPDATE 2-$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag

* Further funding of up to $90 mln to help vaccine roll-out (Wraps stories on GAVI funding, NewLink vaccine trial, adds GAVI CEO comment)

11 Dec 2014

One shot or two? Many questions unresolved in Ebola vaccine race

* Debate over "prime-boost" vaccination as epidemic evolves

11 Dec 2014

RPT-Cubist sales force seen as potential boon for Merck intestinal drug

Dec 9 - In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.

10 Dec 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks